Implications of IVDR on Diagnostic Testing in Europe

This document is a technical report that outlines the implications of the European Union In Vitro Diagnostics Regulation (IVDR) on diagnostic testing and the pharmaceutical industry. It details the compliance requirements for new and existing in vitro diagnostic devices, emphasizing that all devices must meet IVDR standards by May 2027. The report explains the transition periods for existing devices based on their risk classification and highlights the increased certification requirements under IVDR, including the necessity for Notified Body involvement for the majority of devices. It discusses the challenges faced in implementing IVDR, such as delays in the European Database on Medical Devices (EUDAMED) and the impact on clinical investigations. The report also addresses the evolving landscape of Companion Diagnostics (CDx) in Europe, comparing it to practices in the USA, and notes the potential decline of Lab Developed Tests (LDTs) due to stricter regulations. The document concludes by suggesting that pharmaceutical companies may need to adapt their strategies to ensure the successful adoption of diagnostic tests in the new regulatory environment.